KYMR - Earnings call 2 2023 | Kymera Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Hello, and welcome to the Kymera Therapeutics Second Quarter 2023 Quarterly Results Call. I'd now like to turn the call over to Bruce Mr. Jacobs. Please go ahead.

Bruce Jacobs

Good morning, everyone, and welcome to the Kymera Therapeutics quarterly conference call. I'm Financial Nello Kymera, Jared Head Mainolfi, Chief Officer, Chief joined I'll Gollob, of Jacobs, welcome Medical by to her today President and quarterly Investor Bruce Relations Officer Kymera first and at be our Justine to I'm Koenigsberg, excited Kymera new call. also and CEO; our remarks, we'll questions, do. always we prepared open your After as the call to

remind this everyone management Before include that of like we get outlined that on started, the release. as may statements to make press call I'd forward-looking comments the some in

from Actual the statements events any other and with SEC. those various factors results with expressed that result in filings a future set implied could risks, forward-looking filings company differ Kymera any those SEC and may recent make other materially including the by and of the uncertainties or as forth most

except disclaims With the and not to to update You forward-looking those are Nello. call any statements, statements, required on cautioned undue now any hand obligation said, reliance I'll as to by Kymera over place such that law.

Nello Mainolfi

for of Thanks, fully global last us how and degrader contributes discuss company. quarter everyone, our over review joining we best-in-class you, thank to and today. We're the achieving to it building the progress a Bruce, mission excited made medicines integrated

will remarks. shared progress, I details during Over meetings KT-XXX. more across scientific at on and the relating and our KT-XXX-KT-XXX Jared few including months, and multiple presentations updates overview preclinical share the past an we've clinical work, his of will oncology pipeline to provide world this

pharmacology ALL years. and in in In overcome single pursued mechanism we data inhibitors a the we AML, KT-XXX, pipeline, in MDMX inherent of our our EHA which untrack molecule well-validated many biology patient preclinical durable KT-XXX of been compared against addresses differentiated presented The industry drove target. in most Phase this to first XXX to that has potential cancer MDMX tumor with recent of the dose biopharma the for a of Starting to showed the degrader the clinical small the models June addition that I small demonstrate at limitations critical molecule has study a regressions inhibitor. dosed

on granted was the the program, investigating the AML. which unique of for or KT-XXX, an approach it dose by offers Phase where we both FDA protein KT-XXX, in program also selecting more this a IMiDs substrates, proof this With escalation and studies. strong continuing are their we including STATX, targets in degradation year. mechanism only IRAKX or sharing in drug clinical patients look for exemplifies the which I June, This treatment forward variety genetic and and later pathways of Egosenilos treatment, for to of cancers targets and designation of to of targets targeted stages with believe In best validation in respect our effective option

As and a and reminder, the patient in population. of clinical this and these graduation mechanisms to impact the the evaluate for first-in-class these programs focus profile their is our safety appropriate biological year

the the from or approaching molecules PK/PD activity to programs. preclinical already on populations patients. X translation in these to patient models fidelity the ICML evaluating based Later observed. were believe, we trials, dose-limiting data year, shared We antitumor sufficient without this levels, data antitumor in toxicities at provide preclinical both were any target additional the are to At shared intend showing we encouraging achieve models activity recently we target that demonstrated for June, degradation of data meeting from

driven good a which of such IRAKX XXXX. high of very diseases inflammatory the medicines quarter initiate about potentially studies first-in-class degrader dermatitis others. with we unmet development with treatment atopic in KT-XXX, IL-XR needs, [indiscernible], expect fourth with We're profile, immune-inflammatory medical for our in the Our is safety both potential and Sanofi, excited of the as partner, with to and Phase diseases patients in HS KTXXXfor lack AD and currently II the oral effective TLR

to designed showed monoclonal Sebi, data AD of in to enable and block parallel compared kinase antipodes the to targeted PK TLR-IL-XR-mediated and to drive is similar tolerability, to for both broadly of and is and signs cytokines symposium the by XXX in to healthy EADP opportunities program inflammation presented and protein programs, that single to our at This this Phase degradation at which more anti-inflammatory recently the the treatment targeting clinical best-in-class that superior IR. associated of the achieved inhibitors and identify in first direct and systemic HS eliminating PD activity clinical to to pathway disease. we and degradation both degrader robust functions transform skin volunteers, scalding RX HS with patients promising kinase effect and In blood demonstrated the AD. continue inhibition I administered Jared from

We build guide and member Chadwick several have will to worked pathways our pipeline our our of year, that multibillion-dollar in serve exciting support and as sharing programs to early who in Along next Dr. Chief address programs sustainable, well-validated of ensure are first-in-class end, resources preclinical team, integrated revenue R&D designed to areas a forward people programs details our we this clinical with later more Day. We as need the To scale of an look potential. scientific progress, these that Jeremy a Officer, and to with development we've fully Operating capabilities that our leadership appointed in patient we significant growth. our on have as recently the company. to key

affairs, he operations. Takeda global development roles drug safety chain held supply where and Jeremy from clinical in joins global leadership us regulatory

Koenigsberg Head As Bruce very mentioned, we're to Relations. and President welcome Justine also happy of Investor as Vice

be XX weeks. in call years you many than the with more in industry, the the she'll spent of on Justine and engaging upcoming

in now pause call more here details update. turning to will recent financial call me over a the oncology Bruce over for the clinical cover our who Let progress to and from programs before turn Jared,

Jared Gollob

I'll months. Nello. in and stand we with a of recap what programs where Thanks, the our brief coming provide we expect clinical

the apoptosis highly have to the investigational dosing to XXX MDMX small begun that We it the be Camper MDMX shown XX% regulator Phase cancers, multicenter molecule to degrader feedback potential patients that unlike ability clinical going most wild-type have induce crucial in growth. with dose escalation we inhibitors intact refocus. and mentioned, loop remains evaluating and PXX. trial is open-label in potent to pre-clinically has the MDMX has modulate recruitment Nello the overcome meaning is of visibility As cell of retained and common or close greater believe well. our a PXX KT-XXX, the to trial, been suppressor I the even to rapidly tumor

strong greater wide small demonstrated XX than first apoptosis in demonstrating in and effective contrast, with improvements of sustained pXX led inhibition. solid to with has molecule the to malignancies high XXX-fold potential function a preclinical dose ALL XXX X and and be activity only of small range and AML molecule of X dosing cell frequently tumors data within upregulation of degradation induction inhibitor compared hours relatively within PXX. an of oral lower led We've XX% MDMX regressions. and tumor tumors XXX inhibitors MDMX to shown to the growth single apoptosis, superior doses in in in EHA intravenously has vitro dosing in and modest to than in of hematological hour XXX MDMX pre-clinically apoptosis administered In inhibition a both June, repeat pXX that greater and presented that XXX additionally, at we administered tumor or activation induction weak more growth models and

with every pulse of of arms is inhibitors safety receiving consists over patients malignancies, II currently dose lymphomas These to preclinical suggest ALL, an X Phase tumors. Phase in of small molecule dosing PK/PD results each the solid in and IV open-label the or comprised IV for malignancies solid and lymphomas ascending ALL. patients weeks. XXX identify doses B tumors the study arm. the clinical is high-grade trial and consists in and I that evaluating Patients myeloid clinic. in regimen The activity refractory potential XXX relapsed and with efficacy advanced dose MDMX improved XXX are I safety, a tolerability, is the and profile with myeloid The patients in of A of administered Phase of once Arm X arm study high-grade doses recommended escalation with has intended

year. will proceed in initial is once the in Arm dose a established arm across I of to start reached pharmacologically maximum until Dosing this We plan and both Phase A, dose from for will later the been escalation B safety clinical mechanism each continue which proof arms dose arm. share at trial and in tolerated parallel data has time active

numerous PTCL. patients ongoing and/or to of May been as evaluate patients our the is as to treatment to including solid a dependent for at date trials, first Phase X solid dosed that hematological tumors transcriptional being with regulator turning of KTXXX clinical trial, Now the ICML, other levels June, is diseases. cancers tumors. mean as XXX safety, and the data activity is CTCL X STATX doses XXX solid and of PK/PD with In cutoff XX trial inflammatory lymphomas, designed with The I as dose weekly received clinical X, in STATX and to oncology has the that Kymera of shared developed well relapsed of XXXX, a tumors. adult tolerability, malignancies across refractory and well X and autoimmune leukemia the of linked patients

accrual DLX at degradation that of While activity be open with in efficacious were there inflammatory peripheral with regulation preclinical through the and is close is found and substrate Phase cells plasma to blood from eclosiilos. shared mean knockdown in led that profiles those the study. stage in dose-limiting dose fourth in still for dose the were tumors. across was and that DLX I that antitumor novel observed to prop data We level stat to image biomarkers up broadly blood. dose time, models. both down mononuclear levels liquid reaching ongoing, IRAKX at ICML reduction no demonstrated pathway degradation predicted exposure recruiting of a escalation maximum The inhibition X degrader reported increased with toxicities heterobifunctional KT-XXX levels stat XX% to solid targets evidence of at of dose-dependent and Degradation near

interferon trial the against TLR patients IV X was levels dose X relapsed have as once refractory with an Hodgkin to of the the fourth lymphoma. shared both weeks we completed the the address evaluate to ICML PK/PD is been In and/or first INR patients. infusion malignancies. The conjunction activity as to designed and Phase I XXX was designed MYDXX of X mutant and type B-cell synergistically the safety, pathway activity tolerability, XX For to administered clinical broaden clinical that with meeting, adult X, every B-cell June accruing and

At function zone cell tX diffuse mean patients follicular IRAKX DLX with reported all Data to X through patients B-cell had a mono except across those were across that blood dose. to XX% levels who of dose-dependent were reaching received large X point, a in with cellular lymphoma, single lymphoma cells of one mutation. MYDXX efficacious. doses, DLX whom cross close achieved exposure after lymphoma, transformed B marginal dose, and including XXX treated plasma to increase wild-type for and X.X be XX,XXX like peripheral a gain showed plasma degradation up of MYDXX predicted and plastic lymphoma, of activated

of at MYDXX with dose-limiting Degradation mutant the antitumor The of consistent or were portion patient KT-XXX and antitumor escalation in neutropenia that knockdown with there later ICML look associated KT-XXX the patients. profiles levels the We were lymphoma showed to this no drug-related dose toxicities a models observed study. ongoing, activity year. of at I respective and in population Phase activity lymphoma. their recruiting We DLXX broad target preclinical forward trial sharing of is data evaluating B-cell populations

II studies commence AP. first are advanced and in Sanofi in shortly which in are AD, Phase HS XQ by KT-XXX in to HS expected both the followed 'XX, thereafter Finally, being and

to we financial for share Bruce, dosing who our quarter. the I now results more some approach will of hand the share the trial first on comments as details call brief around second will We will the the patients.

Bruce Jacobs

Jared. will turning before cover Thanks, back I to the call Nello quickly for concluding remarks. financials the some

comp recognized the $XX.X sheet to spend revenue operating amount quarter expenses, partnership that approximately from reflects of the total any approximately we revenue, Of compensation, collaboration With milestones. several a of was million, at the $X.X reflects the the quarter, That balance $XX.X R&D cash the for over revenue of of million. XXXX. R&D of respect the to represented quarter, million recognize potential For the the X% expect deferred the and adjusted noncash comparable end excludes that, excluding quarter our stock-based which next stock-based in years, was we on million $XX first million. future $XX.X receipt increase

spending the the compensation which our of from comp, exited amount and reflects adjusted balance side, G&A with approximately stock-based excluding stock-based was first quarter cash the We first equivalents for comparable the a of represent million in spend On G&A million. the of a again, quarter XXXX. cash the of $XX.X noncash $XXX increase X% million, $X.X quarter $X.X million,

to we I'll back As we shared second KT-XXX, first start related II believe occur includes we earlier milestones that expected X the the half that call which turn trials extends XXXX. Phase projection only runway the today stated to cash Nello. of in of now year, in XXXX of our are to the into both the for

Nello Mainolfi

Thanks, Bruce.

in we're the said, made progress in well clinical as indications KT-XXX II oncology X excited I Phase soon on we've be programs. with As by to as our very

in our on treatment to second of enhance gives updates so We will and patients' look Our the us untapped company we I hand pipeline, the powerful potential your the and to forward TPD this programs, the the clinical clinical take able microphone generating rapid of to disease year. the will on improving can advancing progress momentum sharing capitalize be platform to that building operator modality Kymera science of our of questions. exciting now the and in lives. confidence half

Operator

line comes TD Frahm of question first from Cowen. Your Instructions] the [Operator from Marc

Marc Frahm

larger you that your are to you kind only expected this approach be later off kind a and of maybe is of a set different as with the clinical population. of rest of of Monotherapy fraction relevant Can for opportunity you this responses a how look dose start selection than segment KT-XXX. hypothesis bit get the plan to Maybe the data to year?

Nello Mainolfi

Thanks, Marc.

here. Nello So

just first part I'll take and pass I'll of question, the So maybe then the to Jerry. it

so first clinical encompasses tumor and with everybody, opportunity remind and to SAT solid our opportunity, which X program, oncology our just of tumor outside So a with a livid opportunities endeavor started KTXXX.

obviously, hypothesis we're So have clear a pursuing indications, in the potential across opportunity several that we clinic. broader it's and

leukemia, one have concept past, mind, leukemia in earliest obviously that also of first of PTCL, in CTCL one, is, which a lead our activity single-agent cell The that lymphoma subset T the the could is to in discussed proof LGL which we've subsets.

agent, on is single or that focused opportunities rationalize we're X effects fact able pre-clinically because mutation when single we by activation. KTXXX patients have can have translationally those to achieve we've we many why our a we antitumor reason degrader, seen subsets weeks, those particular actually a either it or as in The indications every statutory dose profound the as agent once week even once pathway and that

sensitivity biomarker a activity well in So as we those biomarker have as opportunities.

dose The well tumors. I particular those as Phase escalation subtypes includes as solid

We've data externally back in said it's past, tumors, haven't past, in on that As that We've in so preclinical now based combination. yet, our with immune solid targeted agents therapy. your the mentioned I've we are with opportunities about just clear. talked all discussed combination and we so to circling the question, said the in combination

that PTCL assume about patients With think II meant might So of in to escalation, Jared on a patients we in later handful to will LGL. you how dose, we Phase of regards antitumor let the a activity comment responses, from dose terms I'll come of past, the I to Phase year in said and being terms of from I talk we include maybe the expect CTCL, single-agent that these about activity, subset that. in selecting, able

Jared Gollob

Sure.

our and in We've of for safety. our especially XX% that or at a on data, Marc, with antitumor T greater associated So stat dependent combination always activity. be hours preclinical that PD we will that XX dose or selection X malignancies looked of based cell to XX sort these stated we've where not found

that us tumor XX% tumor sort aim that and/or get our in we at So lasting. blood gives in biopsies, profile, can or be that's least prior greater where dose to a able to is to knockdown of a get

of a favorable the the I PD able into XX that's to profile to hours be to sort Phase with profile, safety we that take want associated that in XX a expansion.

a sense a be that possible, Phase the at PD right level slated of T likely as like handful these I PD next those a doses and which If can Phase with dose II combination PTCL these cell now will confidence of in our of mentioned, be So malignancies that safety us CTCL, of along in with the to being as few LGL to phase, us see that as cell a dependent if patients in recommended giving more population are bringing safety. expansions, into tumors. able that well would patient Nello see which we the STATX responses sort target give dose malignancies, in are are in even solid and T

Marc Frahm

And maybe you just walk question, get postal depth Okay. That's that think topic there? to very a long But you at to Kind but MDMX, for need of you of minimum the how perdition what's of the want helpful. kind similar be through do dosing. and with then XX%? --

Nello Mainolfi

needed, this, -- then start can add. I mean so if I'll and Jared

the thing nice a in from really of gene, all is rapid program obviously, know, we how a trying and what complete developing on case, degradation, variety which what counter we've gene about dilution in then this as reversible. we're to replicate cancer the gene leads and type, is seen it, is the we've have observed So the is wild genetics, MDMX that experimentally, cells reliance wide this PCI Protein MDMX ablation and to of irreversible.

need the see you're activity. that do is deplete asking to target you question to the then So long how

X of those a as hours our so need while you degrader every and degradation as in a this is commitment as -- XX to few robust programs, exposure hours needs once actually, drive pre-clinically death, degradation weeks we sufficient to particular hours a to in this and to that way, apoptotic to that that So profound for with single-digit only response. little apoptotic models what X know, or to XX drive for a leads seen strong X to be sustained cell in we've other it's in either hours order program, hours,

Operator

the question next Canino comes from Your of from line Bradley Stifel.

Bradley Canino

PK/PD, to green by clinical that to degradation you potential going that asset on KT-XXX, separate a need order getting pursued expect I/II to INI a we based you're the prepare Phase kinetics now dial study healthy I&I a For altogether? in STATX for on the handle a in should you models is to volunteer your this Or be open study? to

Nello Mainolfi

Brad, that early Day thanks. great most and as but meet This is when answer question now late most that, year level to an next. in this a I going we hopefully, likely high R&D I think I'm likely then said,

more can I cover assets as I into think a we immunology formulations. as other that that now and both potential for well or say will we're details transition hopefully, XXX But particular right other opportunities with question. of evaluating

where it is leave investigating. that. I'll maybe at we're So This

PD, honest I this really But I good underestimated and is we've been seen importantly, only think programs, has on that what be in we company is PK take this multiple the which constant which to from not now more safety. for be to with study, but Phase translation not

broad has comfortably obviously very much place a first-in-class clinical plan application. oncology target we for study biological that in more can of we're now feel we So outside where a

if I about. hopefully, idea what but an thinking we're answer you this can sorry, with about it gives So details,

Bradley Canino

look that right. forward all I update. That's to

where that you on recovery knowing data think is small prior ask the also molecule about and me When MDMX. target the from blood the Let your population count AML inhibitors in the particularly then impact to for for those What patients. going platelet looking a you continued look important profile be is in rates first development? are thrombocytopenia terms to of at in this see confidence safety

Nello Mainolfi

it. like the Jared team development people question, to to this question, think which to let I actually I but your don't so word, on still use add something would opportunity your I say want I'll clinical do is I Brett. Thanks, our Yes. elegant has but -- take specifically designed, comment

clinically of you plan in idea is, these both other was you ALL malignancies, escalation liquid readout challenging the elegant escalating right AML, activity and plan the other sometimes active dose tumor now, does is from dose because evaluate until that solid reached An doesn't safety on and so the or quite more feel safety the the not PK/PD clinically the mentioned, and the liquid the tumors unnecessarily AML activity. as we're we type assessment to and different, the safety myeloid know context the solid to and entered the active only as tumors, space and indications and in we've we're split that clinical the influence so already tumors when

activity Kymera that degradation way allow or to MDMX the is this evaluate as that first in can within should a One degradation question development, the the build in clinical us we recovery with in allow weeks meaning clinical early answer I rapid which with works, in us of that MDMX to and investigation. thing molecule the Phase as programs other this believe is, we I the I PCX should tumor would X said, say we index that late clinical therapeutic other a sensitive pipeline, Phase all types,

possibly related But that's one expect upregulation... program. pXX from willing at obviously to programs. therapeutic investing build will to and how that maybe might a make the If able to of ourselves, our the is hugely can specifically comment I this is demonstrate think events Phase other really our confident goal show this we're you And I lot and what in we're be to develop program Our and thrombocytopenia all philosophy on that Jed, to to de-risk not, ability the that will we and allow index looking of be if that around money of us decisions. study, will

Jared Gollob

what weeks, with and the Novo of of of is and/or expectation our Well, inhibitors, said, than being superior alluded you the to, once MDMX myelosuppression less should depth based this said, myelosuppression tox as of seen is Sure. sort as on myelosuppression index. much with tolerability our that small GLP be every I therapeutic duration just just hit-and-run the of which higher. give approach us that course, think is X molecule data, a of With our will in AML, dosing

the myelosuppression fact, you're an and responses, In would complete on of see that blast so out we've the expect tumors degree responses, solid how clearing these clinicians is why separated does having looking separate from ALL effect view bone arms, then malignancies arm X and different myeloid as one to of a and clinical level the a at hopefully in high-grade and terms to certain marrow lymphomas because there tolerability that's usually lead myelosuppression. of

because allow GI to see more tox depth less likewise, inhibition. to less So we solid molecule a toxicities which and of MDMX in may patients better that see expect lymphoma and in again, that dose-limiting well do drug solid with do would developing us which be that been of to compared in could in inhibitors tumors we're the telling dosing and their to we're by a be the But index, as tumors, that us -- have myelosuppression. in thing the give myelosuppression response as in small patients, limited traction myelosuppression myelosuppression duration population, particular us and the we to we therapeutic a good seeing would that expect AML be

Operator

Your next question from the of comes Sachs. from Goldman Shibutani line Chris

Chris Shibutani

questions. X Great.

trials of Is possibly today guys, mix. by the perhaps reassuring be 'XX, Phase time a in categories, Bruce, you has potentially I clear, if in other seemed of progresses? start in was case? going committed, you've line to that guys the look understand perhaps biologically, cetera? it Ralupus, we've to founding milestone little is any of the think both to bit that the But tool we And trial as Nello less through into I or is you that to I payments following what had that if certainly conversation of it June clarity gotten formally terms this go KT-XXX, this think work in AD kind HS, at the end a XXX Sanofi compounds was on So And should commence that update and that will indications. et have type rationales additional other sort additional of to highlighted then, advancing program as broader are year. that about know mechanistically, I

Nello Mainolfi

Chris. Thanks, Yes.

X answer think some elegant, let and Bruce X that milestone questions I'll and of was had or So answer these, very then in like there I you I'll the question.

first to one, collaborator in the so we've that to HS Phase was clarify we of time was the Phase start. for that not development as named also of to study I did further, months II II as So least AD XXXX said we've going yes, X take They just Sanofi commit study. be to the past point to initiate that at Phase did exact a KT-XXX, a December there one but months, clinical over said an and to Phase X III study, since collaborations, we what was were commitment not initiate

been would that have clear not in was It XXXX.

finally XXXX. II was that happen start So what we're updating the today of in will AD also Phase

will AD Both second. will be them be in So fourth quarter start and HS XXXX. of first, of will

we we to are opportunities details fit moment so on But and degrader. progress, more I let of us and to those mean, to we also mechanistically will an Sanofi feel other that initiation thank details. the can indications rest study. think discuss I at are that on II able We're to want collaborators, both more regards things for to share probably assured before both as I we clinically that other RX allowing share And of other this we, opportunities. as Bruce's to both, there the profile feel both accelerating that be speak strategies. updating continue milestones. just for With And Phase the comment the I second not

Bruce Jacobs

Chris. thanks, This and Yes, is Bruce.

clarify to the milestone. on Just

in past said before said X the by and hadn't certain at Phase II is a patient least we first we've milestones and what does number, that So the to commented up that. generate indication

included about in are additional additional heard say X initial should or I then our and was the other that and that, targeting you generate I think first AD might that in we ask contemplated but milestones no I program the Beyond the HS runway IRAKX agreement. the milestones, guidance, for molecules collaboration

And haven't updates work We critical are that's think and time generate to well. I as is us well. hear on something has events you'll what milestones specifically over the the timing. potential those But so said the there as just that from ongoing

Chris Shibutani

Great, said in update there XXXX. agreement agreement, and collaboration collaboration you that was of an November initial to

in contemplated this still that's So recent most correct? active agreement,

Bruce Jacobs

comment amendment, the remain the we compound we aggregate the milestones that respect Yes. that made that the includes unchanged, Exactly. time well. may generated be the at follow-on to When as discussed molecules with and

total aggregate the unchanged. So remains

Chris Shibutani

Confirmation Appreciate reassuring it. progress.

Operator

next Schmidt from the comes line Michael from Your question Guggenheim. of

Michael Schmidt

cyclic where X on a had updated looks the expectations how later tracked neutrophil about bit year I the for you're has already and talk also target neutropenia it the like I seen data at this based recently, update recovery in scope that. achieving and ICML clinical expectations dose degradation the on or Can one dosing level with talk Phase about of KT-XXXX, your at we've you X. perhaps the

Nello Mainolfi

Thanks, Michael.

really benefits oncology in escalation the establish important signs it case, for clinical safety as With Jerry is this let as of second your of of and goal the in oncology, regard dose hypotheses the I'll in with safety study, the continue would you escalation development, complete especially the the to also the said, a I to programs, of address to early start question, of so I'll both programs is solidify know, your as and and PK/PD of antitumor maybe part portion activity PK/PD. we to expectations, goal providing then know, first question. you potentially part So Phase assess patients. these evaluate and to But dose

we'll programs, and to, of for establish B-cell both XXXtbMYDD-mutant and part as and CTCL tumor signs we the dose old activity. hole of So of escalation a in recruiting for expect again, patients handful lipid that XXX order PTCL us solid the antitumor cohorts we're of of and that have early for out the lymphoma out for

of hope say, be the to a going the What a and is because expectation, better obviously to sensitive able to safety and activity, antitumor and sound believe to activity, which rates mechanisms, of be complete of handful we able scientifically beyond. of as degradation cohorts design to to is to where first-in-class population, being activity on later to to set part of we terms these on correlate fit the in in mechanisms. to escalation evaluate what study year. response our extend discuss tumors antitumor we the patients being expansion impact is But that hope would have, we're those the PK/PD believe close of metrics and of on we again, dose a hope the again, data that patient now report complete more then clinical studies the are evaluate each So we in able from let's able just to share ability validation study these

So maybe, Jared, you can neutropenia talk question. the about

Jared Gollob

Mike. Sure,

very not indicated us knockdown or of seen see than were in about of but provided was as your XX% expecting which because when back our meeting, we're total mentioned neutropenia, seeing greater So we're utopenia, strong any of encouraging any count. activity the we that amid seeing have not new with in June to decrease neutropenia. toxicities we we around terms Eicosanoids, we you drug-related question ICML those update in some to Yes,

but that recovery we where risen but line which neutropenia, being some GLP We followed to of prior did our decline hasn't we tox in with neutrophils see the weeks decrease dose our some the next have neutrophil it saw seen data, a later. is level in preclinical by to in recovery, X data,

myelosuppression, mid activity activity very this something that being of we clinic, our neutropenia, as so mitigate part course, limited any and being or of IRAKX far strong is has dose-limiting far. XX, think by of been along escalate as is use standpoint of potent encouraging lowering which because without to neutropenia see in have ability with we a especially safety so us dose sort helping KPI at the X-week least the to by ICON successful dosing we important the which from every do schedule, this So

Operator

line the of from comes from Riley question B. next Securities. Your Kalpit

Kalpit Patel

in study planned HUMIRA that then to Would us For trial? on what maybe And patients prior of a trial of planning the the of you follow-up. in color include any And have can allow expected Phase in II HS, that you're use types use give design? the study? you I

Nello Mainolfi

agreed great position Kalpit, at disclosed. think partner not color updates I been on what's on thanks Unfortunately, question. this we It's we're point, soon clinicaltrials.gov. the we've point. there'll in believe it. some add the our a comment might that question. to be with I That's for around able But enough, what At to be

Kalpit Patel

performed room Or option. you you expectations HS? slight there's think and trial that Are have much that match an terms has because it, Got to of efficacy you in what wiggle what as Okay. looking don't in for need historically? you you beat oral or a do HUMIRA looking here are

Nello Mainolfi

we're I'm starting setting great Another glad now question, expectations.

start Obviously, so these that diseases, help be But moderate have an focused is in can activity. with our HS, completely both other say has patients your indications option and the and we would we've seen oral seen let's is question lock which and well indications. far. was populations. can been goal potent obviously, would both and tolerated on with those a patients point, to option that encouraging what In AD. competitive We've works have that and believe to this So agents I that say okay. manage on really approved cases, I that severe both difficult patient in oral especially is well-tolerated at AS

Phase placebo-controlled commercial is repeated complete where study, to in we we the then data if and think the set start particular solid, drug. strategic data that and a can we III once set is I I that the type placement this have study, mean, of is discuss of

to it's say an you'll which discuss active is and easy Kymera and patients to tolerated, be terms future focused All what I planning take and don't that in limited well we going few of But right in studies existing has to about and impact, tolerated looking clinical the the the oral honest, I HSA are in premature both option that hear running be patients say, to oral drugs, fill that have one the commercial again options, other to our drug. of option. for patient can that is to need, a now, in think develop And this both next limited on for well patients regardless are experience, activity that's in would years. been of I

Operator

of from Your comes Purohit from next question Morgan line Vikram Stanley. the

Vikram Purohit

follow-up, and time? that given you're developments on indication? secondly, talk But not X in Sanofi's from potential AD, for to was competitive decision-making has dependent Is of your HS. going this remarks you study Or And in your that what these XXX topic impacted is indications? at HS going one there? for decision-making studies been might I'm around recent beyond other cadence on if at the about So the can discussed design then of additional all thinking the kind patients this apologies and a question through planned we look this But the with of extent recent Sanofi the the enroll around Phase separate sure the now on the you HS just is and indications by missed process that and that in be data to it. II

Nello Mainolfi

and questions, can Vikram. Thanks, address Both both. Yes. I think I great

the for first can't one, speak So Sanofi, unfortunately. I

say, Kymera that organization an development -- in and have opportunities potential we this on can discussing now asset and So years. drug like as this this, few been though, you for partnership other doing what what are any are I a know, case, as own, for our responsible are

have we the are opportunities many to what and speak reinvest times. are So wheel decision-making the But process. don't can't the around HS beyond that the obviously, other AD I conversations to potential

NAD and indications potential from the to from if obviously, the it we my will there and very mechanistically on numerous HS close, are maybe that imagine can first what not, again, list of HS second you can in biologically that and indications and differentiated pathologically HS are I in you have my at exciting other But influence say even might our NAD, that packet that opportunities look perspective, But NAD. that bucket. are mind, that data the is generating influence biologically fit indications some website,

this So at point. maybe at I'll leave that

I well need. that's of I tolerated IPD In this clinical way whether going that our have words around already, designed safety in NAT, other to and question, atman which was this design short there to, would That's safety, to put we is The of these be there as drugs. HS, and what able is to that imagine, The you second studies argue HS and is our drugs, so and inferior the answer not and we superior, it again, goes trial drug are of other goal is and in here. trying study. had can in and II impacted out study the an RKXdegrader the question. the to is evaluate to believe is develop activity design. no. the believe Phase active -- II clinical clear we obviously, clinic, you Sanofi back For clinically COPD again, know, oral question our a of well-tolerated Phase The the my as that answer we're

Operator

Your next Joseph JPMorgan. from the from comes Eric question of line

Eric Joseph

just differentiated where is you cinch and feedback XXX, couple to differentiation can of and feedback sort a MDMX, from be remind bypassing of looking regulation Just just expect on after the us you the this MAX of maybe player degradation cycle and at a that us profile? need look get to X, cycles at would a better use degradation Or enough with perhaps to understanding collection? profile subsequent schedule you to support optimize having degradation to degradation the

Nello Mainolfi

we loop kinetics overcoming so demonstrated experimentally that, it the needs the needs irreversible first feedback which a questions first and to add a We're the of the MDMX Yes, overcome that's the great is the degradation Actually, loop first point. to What impact the of matter follow-up beyond fortunate commitment once first that XXX, loop what means your Because overcome, for retain MDMX you're or with of you anymore, of whether a very so a high have of PXX cells great few the it to biology the only hours, point for degrading level where -- might have few here. degrade feedback today, feedback and another not. hypothesis question. it I to here kind few doesn't be the hours. the to hours, need we does

of of overcoming being hard give because in a is compound really what dose MDMX a it's doesn't to actually pace doesn't it just amount exactly much matter depend were really molecules, the on board. minute is catalytic the really how on of large it re-synthesis degrade you that every able by PXX time the compound Small the can the as of a MDMX dose limited

be to to to suppress X. and cycle we to sell ability MDMX So should that lead able on mechanistically our evaluate

molecule hit antitumor not that and activity we that toxicity, small in why said with us, antitumor drug study. before a needed multiple might degradation you able leads But it's maximal as we show earlier, those importantly, be to know, development, leads just oncology the and cells does Phase I I for standard should inhibitors, happen to that's have to that, cancer limiting hypothesis Now which effect. apoptosis be MDMX cycles to leads to is

dose dose-limiting numbers should going able big early success mechanism we be we that types demonstrate be response studies. eyes. and in inhibitor haven't we're MDMX at to But convincingly about because Z demonstrate to to in X, toxicity, the been Again, other rate it's program tumor sensitive of able be programs right escalation not that able success, before is and hit we to dose, its see that definition this are to for to talk the with this a should least be will patients that Y activity just the able and at population in what antitumor our

Operator

of comes line from Your next UBS Financial. question from Merle Eliana the

Unknown Analyst

been in Jason [ just with majority saw it. so XX June far for is This Freiha trial that ] and the We update from type Ellie. the on

moment And then like I this that expecting have inform should proportion effects continue? you're any how you expect anti-tumor expectations Do for to be? follow-up. change potential to our So a to that

Nello Mainolfi

asked understood didn't your me hear think if but So I I you going I I think you anyway, very it question. tell to answer well, -- and I'm

All with the of the to first I patient everybody, a the patient patients be level patient X, and believe coincidence, a ICML dose in as which a -- mutation June incidence, mutant it a was was X. but midwife, should way, at bit clinically fortunate the it update, I in or or want that actually, meaning the we date, MDD but that remind only be first only was was cohort MIDD-mutant could true I was was it's cutoff a of the that which So or believe, think active. that X were the

That's patients. to see mid-mutant expect patients. in only only on mutant seen where based do We activity strong preclinical MYDXX activity our really data, was

activity, as part have of by I a said, to ability MDD in driven our activity. clinical said demonstrate the the I multiple So earlier, ability to our patients, this antitumor mutant program be as dose to as handful will escalation evaluate

and But again, Phase assume, goal that the is, study. I the generating the question. of safety your which mostly will be rest patients, data, of official hopefully, the I PK/PD really answers While

Unknown Analyst

program, you and ICF do classified discontinuation going expect you as related to the adverse to those showed in how should related Phase those then expect like on forward? you III mechanism, as see the about that Yes, the forward reset you events poster. then going of any think we see to and the the Do that

Nello Mainolfi

I it... ask to going Jared one, heard Jared. this to Hopefully, answer you

Jared Gollob

part bit Well. of Yes, it heard entirely of A little I it. wasn't sort of clear...

Nello Mainolfi

we -- ICML the the terms see the study then rates that's the events to So maybe and in in disclosure, my discontinuation potential Jed up summarize addition. XXX adverse what in XXX of relatedness of did

Jared Gollob

study, adverse mean, events, had we to have who have to not off we the come to in due way adverse events. of haven't eventually people I Yes. discontinuation due a really but much seen

disease terms other and GI we we in what terms future in events. will not modest platelets. rate, expect relatively see may side it of effect push for If adverse terms saw effects we doses preclinical of terms be adverse for So discontinuation come do hopefully, hopefully but example, in progression, studies, like in what Patients there of as of safety higher up we in at did low we for look on on events. pre-clinically reasons

which escalating, to the dose opposed been relatively we've of as seen disease and been adverse related being far, related had many of events, drug So itself. to little we've have that have to as we

studies, those sort sites the continue that's the that to by in there. is able very I we pretreated are disease the out be that for related heavily Phase related how the that have as are been that do tolerated events we thought these itself think patients well whole the really we're point is early have to escalate, dose you're we those X to versus as to drug and seeing to to really to related continue so I safety far, watch see how adverse just we has the that make but and encouraging, Phase to line the onto carefully ultimately at trial. the But profile call up to we'll the these we'll treatment SATCOM to escalate patients. of of be really really, events But difficult see what sometimes It dose seeing level and saw be watching is as patients we investigators enroll are with any

Nello Mainolfi

interest so try time, one the the questions we keep to question, the of to through rest get of we Operator, queue. to in can ask the just can

Operator

Srikripa line of comes question Securities. the from Devarakonda next your from Truist Now

Srikripa Devarakonda

as landscape on NHS programs that of competitive Sanofi's I given lot that the AD. potential in in would know footprint get well could combos Sanofi space great the to to also for AD, a HS and initiating synergistic. answered them evolution have been your of be But respect in thoughts be as and with

combo a potential an pathway, targeting and with instance, partner? be For downstream a the cytokine antibody

Nello Mainolfi

great Yes. question.

saying I patients earlier, mean, others, need both which what in effective is I said would So still start and with, therapies. I again, indications

is time, But one need scientific in say, would a plans If immuno-inflammatory to penetration, the most an But of observer standpoint. so mechanism. because, I really these are they effective simple the think even therapy use and for indulge multiple discussed. mechanisms, of this one Vixen is could I tolerated. merit, scientific the been to limited question be still evolving synergies that's sure, one how my are can't let's well I there immuno-inflammatory a want honest, drugs diseases on there at you there than that not with synergize and across is which at are speak across and those understanding to diseases of say, have has from look If the be opportunities that immune to successful your yes, just point observation potential to more yes,

Operator

comes question line Your of from Wells next Archila Derek from the Fargo.

Derek Archila

that Just KT-XXX you on I&I that or degrader a another for indications? STATX would would follow-up KT-XXX. Or is this potentially you an to question might earlier develop you this purely explore look partner for something to something yourself? Is

Nello Mainolfi

I not immunology did but is to the programs. I and partner in partner XXXX, base strategy to for mean say, is. what the No. thing IRAKX at was the Katy, is not do We should time that company, strategy our that our case right

to not should the next that be is you expect program So partnered. immunology going

partner base case is to -- will reach many you think I inflection expect factors. not But programs our it before think I on depend points that we in these should general... key they

Operator

from from Your next question Shi the Kelly of line comes Jefferies.

Dingding Shi

one clinical programs new targets learnings color objectives X in your indication and more from So of instructed X and the you to provide deliver the is can you how terms the current plan... have of INDs

Nello Mainolfi

we've question. great this what earlier that a first going is lot learned company. the of It's there. years to But specifics X just Yes. numbers from the a generally, the I'm not into I go of said

sure, have degradation, of develop development least to of lot pioneering drug unmet on have that is opportunities, its immuno-inflammatory a I to those early for expectation that inflammatory type at is in I think say particular best-in-class oral potential there'll lots large think options, immune it's the learnings But an so needs, we're pioneering of immune of how diseases. pre-integration focus fair to programs, lot I say discover that expectation we're and the to area. other protein particular inflammatory on be would early in and of and that oral focus be a to indications. degraders the

Operator

of line the from question Law comes Suisse. Credit next from Rich Your

Jin Law

for wondering the... Just

you in Or they narrow lines you the wondering II program are to about patient that positioning XX, of study? stay a the therapy trying specific Just the Phase for thinking will play broad? in study? population Are more how in

Nello Mainolfi

we access of are active I a we're population the of will therapies. at and that Again, development. patients this will developing this Right has a don't further this when At point, talk to by believe reasons by potential we addressed existing believe drug that any be we happen will we now have not that broader and right to safe, in kind earlier. be point... that then labels any -- about served commercial factors limited be clinical positioning, now,

Operator

The last question queue the Bank Meacham from on comes line from of America. the of Geoff

Geoffrey Meacham

on be type follow-up looking mind Other topped your And for you're decisions. immunology, -- for you making BD things some therapeutic of when a assessing areas? if Just than other are may so, what BD these your

Nello Mainolfi

BD say development Question was BD -- or business did a… you like

Geoffrey Meacham

like of KT-XXf-type P.D, collaboration. Yes.

Nello Mainolfi

Yes.

past. So in we've the Lance, this I commented topic, mean on particular

pipeline that indications probably innovative area position to statement for -- innovative deliver broad keep So a to potentially partnerships programs. always think synergistic I'll sustained that about to try apply this Emera right we're innovation now, specifics this is with enabling I I that that's that discuss continue can the I like a concept. entertain say will I effective has platform broad don't would short. engine potential deliver company a But an think therapies... such company and an the at mean, in apply will

Operator

Thank hand for you. queue, over now Showing I'll to further questions the no call remarks. closing Justine in the

Justine Koenigsberg

excited please working and Bruce In me for and out Justin, meantime, to with join follow-up to the the I on of going forward you, many reach team am or thank Thank have you forward. look hesitate any to to everyone, Kymera call. today's don't you, participating questions. very if you

Operator

call and this you, concludes Thank today's conference.

disconnect. now may You

Kymera Therapeutics (KYMR) 3 Aug 232023 Q2 Earnings call transcript